Phase I/II clinical trial - VADS
CA223-001
VADS
Essai clinique fermé
Public cible
Adulte
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in;Advanced Refractory Solid Tumors
Description de l'essai
This is a trial evaluating the efficacy of the combination of nivolumab and lirilumab in patients with recurrent head and neck cancer. This allows patients to receive nivolumab that is marketed in the US based on improved survival.
Liens utiles
CHRISTOPHE LE TOURNEAU
Investigateur principal